B-cell chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow and the most common form of leukemia in adults. It’s characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, marrow, and secondary lymphoid tissues. The major signaling pathways involved in the tumorigenesis and in the resistance to the various anticancer therapies includes Notch, Hedgehog, and Wnt. Indeed, Notch signaling which regulates cell-fate determination during development and maintains adult tissue homeostasis was found recurrently mutated in CCL; about Wnt signaling,it also regulates crucial aspects of cell fate determination, cell migration, cell polarity, neural patterning and organogenesis during embryonic development and the Wnt/PCP pathway contributes to numerous aspects of CLL pathogenesis. Concerning Hedgehog, It exerts its biological effects through a signaling cascade that culminates in a change of balance between activator and repressor forms of glioma-associated oncogene (Gli) transcription factorsand its inappropriate activation occurs in several human cancers, including hematological neoplasms.

Keywords: Chronic Lymphocytic Leukemia (CLL); Bone Marrow (BM); Notch Receptor Intracellular Domain (NICD)

References

1. J Hoellenriegel., et al. “The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia”. Blood 118 (2011): 3603-3612.
2. H Nwabo Kamdje., et al. “Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells”. Blood 118 (2011): 380-389.
3. H Nwabo Kamdje and M Krampera. “Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?” Blood 118 (2011): 6506-6514.
4. D Vlachakis., et al. “An updated evolutionary study of the Notch family reveals a new ancient origin and novel invariable motifs as potential pharmacological targets”. Peer Journal 8 (2020): e10334.
5. JB Samon., et al. “Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells”. Blood 112 (2008): 1813-1821.
6. G Dosen., et al. “Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis”. BMC Immunology 7 (2006): 13.
7. P Hayward., et al. “Wnt/Notch signalling and information processing during development”. Development 135 (2008): 411-424.
8. G Mar., et al. “The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis”. Leukemia 25 (2011): 1665-1673.
9. X Liang and E Song. “The role of bone marrow stromal cells in blood diseases and clinical significance as a crucial part of the hematopoietic microenvironment”. Annals of Blood 5 (2020): 2.
10. M Krampera. “Mesenchymal stromal cell 'licensing': a multistep process”. Leukemia 25 (2011): 1408-1414.
11. N Mesini., et al. “Role of Notch2 pathway in mature B cell malignancies”. Frontiers in Oncology 12 (2023): 1073672.
12. F Liotta., et al. Stem Cells 26 (2008): 279-289.
13. Cuesta-Mateos JR., et al. “Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target”. Frontiers in Immunology 12 (2021): 662866.
14. M Di Ianni., et al. “A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation”. British Journal of Haematology 146 (2009): 689-691.
15. N Dubois., et al. “Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles”. Frontiers in Oncology 10 (2020): 1422.
16. T “CXCL12/SDF-1 and CXCR4”. Frontiers in Immunology 6 (2015): 301.
17. Rosati R., et al. “Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells”. Blood 113 (2009): 856-865.
18. K Cullion., et al. “Targeting the Notch1 and mTOR pathways in a mouse T-ALL model”. Blood 113 (2009): 6172-6181.
19. P J Real., et al. “Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia”. Nature Medicine 15 (2009): 50-58.
20. H Skvara., et al. “Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor”. Journal of Investigation Dermatology 131 (2011): 1735-1744.
21. Heller M A., et al. “Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment”. Cancer Research (2012).
22. J Steele., et al. Blood 112 (2008): 3827-3834.
23. RG Wickremasinghe., et al. “p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies”. Leukemia 25 (2011): 1400-1407.
24. P Secchiero., et al. “Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism”. Blood 113 (2009): 4300-4308.
25. D Lu., et al. “Activation of the Wnt signaling pathway in chronic lymphocytic leukemia”. Proceedings of the National Academy of Sciences of the United States of America 101 (2004): 3118-3123.
26. Filipovich R K., et al. “Evidence for non-functional Dickkopf-1 (DKK-1): signaling in chronic lymphocytic leukemia (CLL)”. European Journal of Haematology 85 (2010): 309-313.
27. Y Logan and R Nusse. "The Wnt signaling pathway in development and disease”. Annual Review of Cell and Developmental Biology 20 (2004): 781-810.
28. Howe T Bromidge. “Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma”. Leukemia Research 30 (2006): 29-32.
29. V Hegde., et al. “Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target”. Molecular Cancer Research 6 (2008): 1928-1936.
30. Wu K A., et al. “The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia”. Pharmaceutics 15 (2023): 958.
31. M Ghia., et al. “Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia”. Blood 133 (2019)2651-2663.
32. V Hegde., et al. “Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma”. Molecular Cancer Therapeutics 7 (2008): 1450-1460.
33. V Kumar., et al. “The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies”. Frontiers in Cell and Developmental Biology 9 (2021): 650772.
34. Sorrentino A., et al. “Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies”. Mediterranean Journal of Hematology and Infectious Diseases 11 (2019): e2019037.
35. M Lopez-Guerra., et al. “The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells”. Leukemia 29 (2015): 96–106.
36. W J Chae., et al. “Dickkopf1: An immunomodulatory ligand and Wnt antagonist in pathological inflammation”. Differentiation 108 (2019): 33-39.
37. Zhu J., et al. “Expression and Role of Dickkopf-1 (Dkk1): in Tumors: From the Cells to the Patients”. Cancer Manag Res. 13 (2021): 659-675.
38. THN., et al. “Soluble Frizzled-related proteins promote exosome-mediated Wnt re-secretion”. Communications Biology 7 (2024): 254.
39. P Janovská and V Bryja. “Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas”. British Journal of Pharmacology 174 (2017): 4701-4715.
40. G Chiodin and F Forconi. “Hedgehog activation in CLL”. Blood 133 (2019)2628–2630.
41. PJ Real., et al. “NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia”. Leukemia 23 (2009): 1374-1377.
42. T Palomero., et al. “NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth”. Proceedings of the National Academy of Sciences of the United States of America 103 (2006): 18261-18266.
43. T Palomero., et al. “The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia”. Cell Cycle 7 (2008): 965-970.
44. Myhrvold A., et al. “Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia”. Oncotarget 9 (2018): 9273-9284.
45. T L Lin., et al. “Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926”. PLoS One 5 (2010): e15262.
46. Gutierrez Jr., et al. “LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis”. Blood 116 (2010): 2975-2983.

Citation

Citation: Armel Hervé Nwabo Kamdje and Hervet Paulain Dongmo Fogang. “Role of Notch, Wnt and Hh Signaling in B-cell Chronic Lymphocytic Leukemia Inside the Bone Marrow Stromal Cells Microenvironment”.Acta Scientific Cancer Biology 8.5 (2024): 30-38.

Copyright

Copyright: © 2024 Armel Hervé Nwabo Kamdje and Hervet Paulain Dongmo Fogang. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.